Rivulet Media Inc (fka RIVU)

[Sage7243]

Dear Primary Posters,

Goodness gracious! Why haven't you folks mentioned the arthritis treatments? If I would have known this, I would have staked my life savings on this. And, I see many trusted advisors on this study, such as The University of Colorado and Cook Biosciences, LLc.

The Bear stated it awhile back: Know what you own.

Anyhow, I would love riches, but if many members of my family could find relief from this family, then I will be a wealthy man indeed.

Health is Wealth!




http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf

See excerpt:



In the published literature, the clinical use of systemic- ally administered SVF cells has been reported in three studies. The first study was a description of 3 patients suffering from multiple sclerosis who received intraven- ous administration of autologous adipose SVF. All 3 patients reported significant improvement neurologically and demonstrated a good safety profile [139]. In another paper, a single patient case report described a remission of rheumatoid arthritis [140]. More recently, a paperdemonstrating one year safety of rheumatoid arthritis patients treated with autologous SVF was published [123]. The general safety of fat grafting is widely accepted in that this is a common procedure in cosmetic surgery [141,142]. The HemXellerate product is an optimized autologous SVF preparation for stimulation of hematopoiesis that is covered by one issued patent and two patent applica- tions. In practice the physician is shipped a kit, which is used to collect adipose tissue, tissue is sent to a central processing facility, and a standardized cellular product is delivered in a ready-to-use manner. Currently the com- pany is developing various uses for the HemXellerate pro- duction in conditions involving suppressed hematopoiesis.